Effectiveness of first-generation HCV protease inhibitors: does HIV coinfection still play a role?

Nicolini, Laura A.^a; Menzaghi, Barbara^b; Ricci, Elena^c; Martinelli, Canio^e; Magni, Carlo^d; Maggi, Paolo^f; Celesia, Benedetto M.^g; Parruti, Giustino^h; Babudieri, Sergioⁱ; Bonfanti, Paolo^j; Falasca, Katia^k; Vichi, Francesca^l; De Socio, Giuseppe V.^m; Salomoni, Elena^e; Di Biagio, Antonio^a; Quirino, Tiziana^b

Objective: HIV/hepatitis C virus (HCV) coinfected patients are usually considered a difficult-to-treat population. The aim of this study was to assess the effectiveness of telaprevir-based andBoceprevir-based treatments with respect to the HIV status.

Methods: A prospective multicentre study was conducted among 22 Infectious Disease centres in Italy. Demographic, HIV and HCV related variables were collected, as well as data on HCV viral decay, sustained virologic response (SVR12) and grade 3–4 adverse events.

Results: Overall, 162 patients (24.7% HIV/HCV coinfected) received HCV treatment. Out of 145 evaluable patients, 57.2% achieved SVR12 (49.5% monoinfected, 78.9% coinfected). HIV coinfection was associated with a slight increase in the probability of SVR12 (adjusted odds ratio 1.66, 95% confidence interval 0.59–4.64,P=0.33). Premature discontinuation rates and adverse events were similar irrespective of HIV status, with the exception of skin reactions, which were more frequently in the HIV group.

Conclusion: In a real-life setting, with a high proportion of cirrhotic and treatment-experienced patients, the overall SVR12 rate was 57.2%. HIV coinfection was not associated with impaired outcome.

European Journal of Gastroenterology & Hepatology:

January 2016 - Volume 28 - Issue 1 - p 37–41